Goran Rakocevic, MD

Goran Rakocevic, MD

Contact Dr. Rakocevic

901 Walnut Street
Suite 400
Philadelphia, PA 19107

(215) 955-7952
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome
  2. Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: Does abnormal jitter predict response to treatment?
  3. Propofol as a Risk Factor for ICU-Acquired Weakness in Septic Patients with Acute Respiratory Failure
  4. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
  5. Severe acute inflammatory demyelinating polyradiculoneuropathy with persistent weakness associated with tumor-like nerve root enlargement
  6. Lower extremity peak force and gait kinematics in individuals with inclusion body myositis
  7. Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis
  8. Thoracic Nerve, Long
  9. Paraplegia following lumbosacral steroid epidural injections
  10. Are repeated single-limb heel raises and manual muscle testing associated with peak plantar-flexor force in people with inclusion body myositis?
  11. Stiff person syndrome improvement with chemotherapy in a patient with cutaneous t cell lymphoma
  12. Pearls and oy-sters: Neurosyphilis presenting as mesial temporal encephalitis
  13. Reply
  14. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue
  15. Autoimmune stiff person syndrome and related myelopathies: Understanding of electrophysiological and immunological processes
  16. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity
  17. Atypical clinically diagnosed stiff-person syndrome response to dantrolene-a refractory case
  18. Reply: Comment on alemtuzumab and inclusion body myositis
  19. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy
  20. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis